Pluri (PLUR) Research & Development (2010 - 2025)
Pluri (PLUR) posted quarterly Research & Development of $3.9 million for Q4 2025, up 35.01% year-over-year from $2.9 million in Q4 2024, and little changed quarter-over-quarter from $3.9 million in Q3 2025.
Pluri (PLUR) Research & Development (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Research & Development for 16 consecutive years, with $3.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development rose 35.01% year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $14.9 million (up 16.48% YoY), while the FY2025 annual figure was $12.9 million, up 3.25% from the prior year.
- Research & Development was little changed at $3.9 million in Q4 2025 per PLUR's latest filing, from $3.9 million in the prior quarter.
- Across five years, Research & Development topped out at $9.0 million in Q2 2021 and bottomed at $2.9 million in Q4 2024.
- Historically, Research & Development has averaged $4.6 million across 5 years, with a median of $4.0 million in 2025.
- Annual changes were most pronounced in 2021 — Research & Development jumped 53.34% — and 2022, when it slumped 42.23%.
- Pluri's Research & Development stood at $6.5 million in 2021, then tumbled by 41.83% to $3.8 million in 2022, then dropped by 11.81% to $3.3 million in 2023, then decreased by 12.37% to $2.9 million in 2024, then soared by 35.01% to $3.9 million in 2025.
- Business Quant data shows PLUR's Research & Development at $3.9 million in Q4 2025, $3.9 million in Q3 2025, and $4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 97.90 Mn |
| 10 | Pluri | 15.74 Mn | 3.26 Mn | 86,000.00 | 3.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Mar 31, 2025 | 3.04 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 3.09 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Mar 31, 2023 | 4.33 Mn |
| Dec 31, 2022 | 3.79 Mn |
| Sep 30, 2022 | 4.27 Mn |
| Jun 30, 2022 | 5.17 Mn |
| Mar 31, 2022 | 6.16 Mn |
| Dec 31, 2021 | 6.51 Mn |
| Sep 30, 2021 | 6.39 Mn |
| Jun 30, 2021 | 8.95 Mn |
| Mar 31, 2021 | 7.67 Mn |